Chemed’s third quarter saw positive market reaction, with results surpassing Wall Street’s revenue and non-GAAP profit expectations. Management attributed the strong performance to robust admissions growth and cost control at VITAS, as well as revenue gains across both residential and commercial segments at Roto-Rooter. CEO Kevin McNamara noted, “The combination of ADC growth and cost containment, particularly with respect to central support costs, drove significant revenue and income growth at VITAS during the third quarter.”

Is now the time to buy CHE? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our top 5 analyst questions from Chemed’s Q3 earnings call

• Brian Tanquilut (Jefferies) asked about nursing availability and wage inflation at VITAS. CEO Joel Wherley said hiring has not been a challenge, and wage pressures have not restricted growth or capacity.
• Brian Tanquilut (Jefferies) followed up on the Roto-Rooter acquisition pipeline and margins. CFO Michael Witzeman explained that while large acquisitions are rarer now, the focus remains on integrating recent deals, which initially have lower EBITDA margins.
• Joanna Gajuk (Bank of America) questioned the impact of paid digital marketing on Roto-Rooter margins. CEO Kevin McNamara acknowledged rising paid lead costs as a structural headwind but noted the brand’s strong repeat business and price per job increases as mitigating factors.
• Joanna Gajuk (Bank of America) inquired about competitive threats from AI-driven search and DIY trends. McNamara said most Roto-Rooter jobs are complex and urgent, making them less vulnerable to DIY solutions, but acknowledged that AI may eventually alter customer acquisition dynamics.
• Ben Hendrix (RBC Capital Markets) asked about the growth of organically generated leads and the use of technology to diversify away from Google. Witzeman described ongoing efforts, including a Roto-Rooter app and tracking AI-sourced leads, to broaden lead generation and reduce reliance on paid search.

Catalysts in upcoming quarters

In the coming quarters, our analysts will be watching (1) the pace at which newly acquired Roto-Rooter territories improve their profitability and integrate into the broader branch network, (2) the sustainability of admissions growth and margin management at VITAS, and (3) Chemed’s ability to contain rising marketing and fuel costs at Roto-Rooter. Updates on digital lead generation initiatives and further acquisition activity will also be key indicators of execution.

Chemed currently trades at $531.22, up from $508.80 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).

The best stocks for high-quality investors

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.